Blood Res 2019; 54(3):
Published online September 30, 2019
https://doi.org/10.5045/br.2019.54.3.210
© The Korean Society of Hematology
Correspondence to : Yang Liang Boo, M.D.
Department of Haematology, Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia
E-mail: coolrontin@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Classical Hodgkin lymphoma (cHL) is a clinicopathologically unique, aggressive lymphoma arising from germinal center B-cells and is one of the most curable hematological malignancies. This study aimed to determine the clinical course, treatment regimens, response rates, and survival data of patients diagnosed with cHL in a tertiary center.
A retrospective review was conducted to include patients with a diagnosis of cHL from 2013 to 2017. Data of demographic and clinical characteristics, treatment regimens, and outcomes were collected and analyzed.
We recruited 94 patients with a median age of 27.0 [interquartile range (IQR), 12] years. Most of the patients were male (61.7%) and 73.4% were ethnic Malay. Nodular sclerosis was the most common histology (77.6%), followed by mixed cellularity (6.4%) and others (16%). The median follow-up time was 28.0 (IQR, 32) months. All patients received chemotherapy but only 13.8% received radiotherapy as consolidation. The doxorubicin-bleomycin-vinblastine-dacarbazine regimen was the most common (85.1%), followed by the escalated bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristineprednisolone-procarbazine regimen (14.9%). Following treatment, 76.1% of patients achieved complete response. The 2-year overall survival (OS) and progression-free survival (PFS) of the entire cohort were 96.5% and 71.1%, respectively. The 2-year OS and PFS for advanced-stage disease were 93.9% and 62.8%, compared to 100% and 82.7% for early-stage disease, respectively (
This study provides insight into the clinical presentation and treatment outcomes among patients with cHL in Malaysia. A longer study duration is required to identify OS and PFS benefits and treatment-related complications for different chemotherapeutic regimens.
Keywords Hodgkin lymphoma, Clinical features, Treatment outcomes, Malaysia
Blood Res 2019; 54(3): 210-217
Published online September 30, 2019 https://doi.org/10.5045/br.2019.54.3.210
Copyright © The Korean Society of Hematology.
Yang Liang Boo1, Helen Siew Yean Ting1, Diana Fui Sing Yap2, See Guan Toh1, Soo Min Lim1
1Department of Haematology, Hospital Sultanah Aminah, Ministry of Health Malaysia, Johor Bahru, 2Department of Pharmacy, Hospital Enche’ Besar Hajjah Khalsom, Ministry of Health Malaysia, Kluang, Johor, Malaysia
Correspondence to:Yang Liang Boo, M.D.
Department of Haematology, Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia
E-mail: coolrontin@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Classical Hodgkin lymphoma (cHL) is a clinicopathologically unique, aggressive lymphoma arising from germinal center B-cells and is one of the most curable hematological malignancies. This study aimed to determine the clinical course, treatment regimens, response rates, and survival data of patients diagnosed with cHL in a tertiary center.
A retrospective review was conducted to include patients with a diagnosis of cHL from 2013 to 2017. Data of demographic and clinical characteristics, treatment regimens, and outcomes were collected and analyzed.
We recruited 94 patients with a median age of 27.0 [interquartile range (IQR), 12] years. Most of the patients were male (61.7%) and 73.4% were ethnic Malay. Nodular sclerosis was the most common histology (77.6%), followed by mixed cellularity (6.4%) and others (16%). The median follow-up time was 28.0 (IQR, 32) months. All patients received chemotherapy but only 13.8% received radiotherapy as consolidation. The doxorubicin-bleomycin-vinblastine-dacarbazine regimen was the most common (85.1%), followed by the escalated bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristineprednisolone-procarbazine regimen (14.9%). Following treatment, 76.1% of patients achieved complete response. The 2-year overall survival (OS) and progression-free survival (PFS) of the entire cohort were 96.5% and 71.1%, respectively. The 2-year OS and PFS for advanced-stage disease were 93.9% and 62.8%, compared to 100% and 82.7% for early-stage disease, respectively (
This study provides insight into the clinical presentation and treatment outcomes among patients with cHL in Malaysia. A longer study duration is required to identify OS and PFS benefits and treatment-related complications for different chemotherapeutic regimens.
Keywords: Hodgkin lymphoma, Clinical features, Treatment outcomes, Malaysia
Kaplan-Meier survival curve for 2-year OS and PFS for the entire cohort of patients.
Kaplan-Meier survival curve for 2-year OS and PFS for patients with early-stage and advanced-stage disease.
Kaplan-Meier survival curve for 12-month OS and PFS for patients treated with ABVD and escalated BEACOPP as first-line treatment in newly diagnosed HL.
a)B symptoms (fever >38℃; unexplained loss of >10% of body weight over the past six months, and presence of drenching night sweats)..
Abbreviation: IPS, international prognostic score..
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisolone, procarbazine..
a)Two-sided log-rank test. b)
a)Simple cox proportional hazard regression. b)Forward likelihood ratio multivariate cox proportional hazard regression. c)Missing data=7..
d)
Abbreviations: CI, confidence interval; HR, hazard ratio..
Jisu Oh, Doyeun Oh, Seon Ju Lee, Jeong Oh Kim, Nam Keun Kim, So Young Chong, Ji Young Huh, Ross I. Baker, on behalf of the Korean TTP Registry Investigators
Blood Res 2019; 54(3): 218-228Erin-Siobhain R. Currin, and Ajay K. Gopal
Korean J Hematol 2012; 47(1): 8-16Dae Seog Heo, Ji Yeon Baek, Sook Ryun Park, In Sil Choi, Sang, Il Kim, Dong, Wan Kim, Jee Hyun Kim, Sung, Soo Yoon, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim, Dae Seog Heo
Korean J Hematol 2005; 40(1): 8-14
Kaplan-Meier survival curve for 2-year OS and PFS for the entire cohort of patients.
|@|~(^,^)~|@|Kaplan-Meier survival curve for 2-year OS and PFS for patients with early-stage and advanced-stage disease.
|@|~(^,^)~|@|Kaplan-Meier survival curve for 12-month OS and PFS for patients treated with ABVD and escalated BEACOPP as first-line treatment in newly diagnosed HL.